Skip to content
2000
Volume 33, Issue 7
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Introduction

Hepatitis B Virus-Related Hepatocellular Carcinoma (HBV-HCC) constitutes a formidable global health challenge, demanding an in-depth understanding of its intricate pathogenesis. The research conducted a comprehensive analysis of the multifaceted relationship between HBV-HCC. It further examined the potential of which could serve as an effective adjunct therapy in treating HBV-associated HCC. Our approach integrates network pharmacology, pathway analysis, molecular docking, and dynamics simulations, offering an intricate unraveling of the molecular mechanisms that underlie 's potential impact on HBV-HCC.

Methods

Additionally, we delve into microarray analysis to unearth differentially expressed genes (DEGs) associated with HBV-HCC, molecular docking to validate compound interactions with key proteins, and molecular dynamics simulations to elucidate the stability of these interactions. These multifaceted approaches enhance our understanding of 's therapeutic potential.

Results

This work represents a significant advancement toward the development of more effective strategies for the management of this challenging disease, offering a comprehensive exploration of 's therapeutic prowess. Within this multidimensional framework, we identify CDK1, SERPINE1, and PTGS2 as promising therapeutic targets, shedding light on the molecular intricacies of disease progression. Further, Homoorientin from 's demonstrates a strong binding affinity with proteins CDK1, SERPINE1, and PTGS2, suggesting a potential synergistic effect in therapeutic applications. Moreover, our enrichment analysis uncovers a rich tapestry of pathways enriched in HBV-HCC, providing insights into the multifaceted landscape of disease complexity.

Conclusion

These findings not only pave the way for potential targeted therapies but also deepen our comprehension of the intricate molecular underpinnings of HBV-HCC.This work represents a significant advancement toward the development of more effective strategies for the management of this challenging disease, offering a multifaceted exploration of 's therapeutic potential.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673305923240723073156
2024-07-26
2026-02-26

  • From This Site

    /content/journals/cmc/10.2174/0109298673305923240723073156
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BruixJ. LlovetJ.M. Hepatitis B virus and hepatocellular carcinoma.J. Hepatol.2003391596310.1016/S0168‑8278(03)00140‑514708679
     [Google Scholar]
  2. SureshD. SrinivasA.N. KumarD.P. Etiology of hepatocellular carcinoma: special focus on fatty liver disease.Front. Oncol.20201060171010.3389/fonc.2020.60171033330100
     [Google Scholar]
  3. EdmundsW.J. MedleyG.F. NokesD.J. O’CallaghanC.J. WhittleH.C. HallA.J. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areasr.Epidemiol. Infect.1996117231332510.1017/S09502688000014978870629
     [Google Scholar]
  4. ZhuZ.Z. CongW.M. LiuS.F. XianZ.H. WuW.Q. WuM.C. GaoB. HouL.F. ZhuG.S. A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection.Cancer Lett.20052291778310.1016/j.canlet.2005.04.01415979781
     [Google Scholar]
  5. AnP. XuJ. YuY. WinklerC.A. Host and viral genetic variation in HBV-related hepatocellular carcinoma.Front. Genet.2018926110.3389/fgene.2018.0026130073017
     [Google Scholar]
  6. HsiehY.H. HsuJ.L. SuI.J. HuangW. Genomic instability caused by hepatitis B virus: into the hepatoma inferno.Front. Biosci.20111612586259710.2741/387421622197
     [Google Scholar]
  7. SuputraI.G.L.R.D. SaputraI.W.E. Non-cirrhotic hepatocellular carcinoma with duodenal metastasis in chronic hepatitis B: Case report.Int. J. Scient. Adv.20223575876110.51542/ijscia.v3i5.14
     [Google Scholar]
  8. LiuL. ZhaoY. QiX. CaiG. HeC. GuoW. YinZ. ChenH. ChenX. FanD. HanG. Transjugular intrahepatic portosystemic shunt for symptomatic portal hypertension in hepatocellular carcinoma with portal vein tumor thrombosis.Hepatol. Res.201444662163010.1111/hepr.1216223679937
     [Google Scholar]
  9. GhoshS. BhowmikS. MajumdarS. GoswamiA. ChakrabortyJ. GuptaS. AggarwalS. RayS. ChatterjeeR. BhattacharyyaS. DuttaM. DattaS. ChowdhuryA. DhaliG.K. BanerjeeS. The exosome encapsulated microRNAs as circulating diagnostic marker for hepatocellular carcinoma with low alpha-fetoprotein.Int. J. Cancer2020147102934294710.1002/ijc.3311132441313
     [Google Scholar]
  10. YarnellE. AbascalK. Dandelion (Taraxacum officinale and T mongolicum).Integr. Med.200982120
     [Google Scholar]
  11. Kania-DobrowolskaM. BaraniakJ. Dandelion (Taraxacum officinale L.) as a source of biologically active compounds supporting the therapy of co-existing diseases in metabolic syndrome.Foods20221118285810.3390/foods1118285836140985
     [Google Scholar]
  12. JoachimJ.H. MehtaK.J. Hepcidin in hepatocellular carcinoma.Br. J. Cancer2022127218519210.1038/s41416‑022‑01753‑235264787
     [Google Scholar]
  13. SharbidreA.A. Role of phytoconstituents in the hepatocellular carcinoma management: Current perspective, challenges, and future perspectives. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma.Elsevier20223175196
     [Google Scholar]
  14. RenF. WuK. YangY. YangY. WangY. LiJ. Dandelion polysaccharide exerts anti-angiogenesis effect on hepatocellular carcinoma by regulating VEGF/HIF-1α expression.Front. Pharmacol.20201146010.3389/fphar.2020.0046032322211
     [Google Scholar]
  15. LisB. OlasB. Pro-health activity of dandelion (Taraxacum officinale L.) and its food products history and present.J. Funct. Foods201959404810.1016/j.jff.2019.05.012
     [Google Scholar]
  16. NakamuraK. KNApSAcK-3D: A three-dimensional structure database of plant metabolites.Plant and Cell Physiology2013542e410.1093/pcp/pcs186
     [Google Scholar]
  17. MohanrajK. IMPPAT: A curated database of Indian medicinal plants, phytochemistry and therapeutics.Sci. Rep.201881432910.1038/s41598‑018‑22631‑z
     [Google Scholar]
  18. GfellerD. Swiss Target Prediction: A web server for target prediction of bioactive small molecules.Nucleic Acids Res.201442Web Server issueW32W3810.1093/nar/gku293
     [Google Scholar]
  19. KuhnM. STITCH: Interaction networks of chemicals and proteins.Nucleic Acids Res.200736Database issueD684D68810.1093/nar/gkm795
     [Google Scholar]
  20. CloughE. BarrettT. The gene expression omnibus.Methods Mol. Biol.201693110
     [Google Scholar]
  21. ShannonP. Cytoscape: A software environment for integrated models of biomolecular interaction networks.Genome Res.200313112498250410.1101/gr.1239303
     [Google Scholar]
  22. RehmanA. Unveiling the multi-target compounds of Rhazya stricta : discovery and inhibition of novel target genes for the treatment of clear cell renal cell carcinoma.Comput. Biol. Med.202316510742410.1016/j.compbiomed.2023.107424
     [Google Scholar]
  23. RehmanA. Identification of molecular mechanisms underlying the therapeutic effects of Celosia Cristata on immunoglobulin nephropathy.Comput. Biol. Med.2022151Pt A10629010.1016/j.compbiomed.2022.106290
     [Google Scholar]
  24. DennisG. DAVID: database for annotation, visualization, and integrated discovery.Genome Biology200349111
     [Google Scholar]
  25. BasavarajappaG.M. Therapeutic effects of Crataegus monogyna inhibitors against breast cancer.Front Pharmacol202314118707910.3389/fphar.2023.1187079
     [Google Scholar]
  26. AloufiB. Exploring therapeutic targets and drug candidates for obesity: A combined network pharmacology, bioinformatics approach.J. Biomol. Struct. Dyn.2023912210.1080/07391102.2023.2265491
     [Google Scholar]
  27. DallakyanS. OlsonA.J. Small-molecule library screening by docking with PyRx.Chemical biology.Springer201524325010.1007/978‑1‑4939‑2269‑7_19
     [Google Scholar]
  28. TianW. CASTp 3.0: computed atlas of surface topography of proteins.Nucleic Acids Res.201846W1W363W367
     [Google Scholar]
  29. StudioD.J.A. Discovery studio.2008Available from: https://discover.3ds.com/discovery-studio-visualizer-download
  30. YuanS. ChanH.S. HuZ.J.W.I.R.C.M.S. Using PyMOL as a platform for computational drug design.WIREs Computational Molecular ScienceWiley Interdisciplinary Reviews201772e129810.1002/wcms.1298
     [Google Scholar]
  31. GoddardT.D. UCSF ChimeraX: Meeting modern challenges in visualization and analysis.Protein Sci.2018271142510.1002/pro.3235
     [Google Scholar]
  32. PapadakosS.P. MachairasN. StergiouI.E. ArvanitakisK. GermanidisG. FramptonA.E. TheocharisS. Unveiling the yin-yang balance of m1 and m2 macrophages in hepatocellular carcinoma: Role of exosomes in tumor microenvironment and immune modulation.Cells20231216203610.3390/cells1216203637626849
     [Google Scholar]
  33. DubergA.S. LybeckC. FältA. MontgomeryS. AlemanS. Chronic hepatitis B virus infection and the risk of hepatocellular carcinoma by age and country of origin in people living in Sweden: A national register study.Hepatol. Commun.2022692418243010.1002/hep4.197435503810
     [Google Scholar]
  34. WhiteM.C. HolmanD.M. BoehmJ.E. PeipinsL.A. GrossmanM. Jane HenleyS. Age and cancer risk: A potentially modifiable relationship.Am. J. Prev. Med.2014463Suppl. 1S7S1510.1016/j.amepre.2013.10.02924512933
     [Google Scholar]
  35. KirkG.D. BahE. MontesanoR. Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa.Carcinogenesis200627102070208210.1093/carcin/bgl06016679307
     [Google Scholar]
  36. GuptaS. Human Viruses: Infection, prevention and potential target (s) for therapy : A comprehensive review.Human Viruses: Diseases, Treatments and Vaccines: The New InsightsSpringer2021354
     [Google Scholar]
  37. ZhuM. LiangZ. PanJ. ZhangX. XueR. CaoG. HuX. GongC. Hepatocellular carcinoma progression mediated by hepatitis B virus-encoded circRNA HBV_circ_1 through interaction with CDK1.Mol. Ther. Nucleic Acids20212566868210.1016/j.omtn.2021.08.01134589285
     [Google Scholar]
  38. DivellaR. MazzoccaA. GadaletaC. SimoneG. ParadisoA. QuarantaM. DanieleA. Influence of plasminogen activator inhibitor-1 (SERPINE1) 4G/5G polymorphism on circulating SERPINE-1 antigen expression in HCC associated with viral infection.Cancer Genomics Proteomics20129419319822798504
     [Google Scholar]
  39. Lara-PezziE. Gómez-GaviroM.V. GálvezB.G. MiraE. IñiguezM.A. FresnoM. Martínez-AC. ArroyoA.G. López-CabreraM. The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression.J. Clin. Invest.2002110121831183810.1172/JCI20021588712488433
     [Google Scholar]
  40. MirzayansR. New insights into p53 signaling and cancer cell response to DNA damage: Implications for cancer therapy.J. Biomed. Biotechnol.2012201217032510.1155/2012/170325
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673305923240723073156
Loading
An Extensive Pharmacological Evaluation of New Anti-carcinoma CDK1 and SERPINE1 Targeted Compound Homoorientin from T. officinale's with In-depth Molecular Docking and Simulation Studies
Curr. Med. Chem. 33, 1361 (2026); https://doi.org/10.2174/0109298673305923240723073156
/content/journals/cmc/10.2174/0109298673305923240723073156
/content/journals/cmc/10.2174/0109298673305923240723073156
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): Hepatitis B virus; hepatocellular carcinoma; jaundice; molecular modeling; network pharmacology; T. officinale

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test